News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

XDx, Inc. Announces Blue Shield of California Considers AlloMap(R) Medically Necessary for Monitoring Heart Transplant Rejection



8/17/2011 8:54:42 AM

BRISBANE, Calif.--(BUSINESS WIRE)--XDx, Inc., a molecular diagnostics company focused on the development and commercialization of clinically differentiated, high value non-invasive gene expression tests to monitor immune-mediated conditions, today announced that Blue Shield of California considers AlloMap® “medically necessary” for monitoring heart transplant rejection more than one year post-transplant. By assuring coverage of AlloMap for its eligible patients, Blue Shield of California recognizes the clinical utility of this non-invasive method of determining the risk of rejection in stable heart transplant recipients.

Read at BioSpace.com


comments powered by Disqus
XDx, Inc.
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES